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ABSTRACT
The Ras/Raf/MEK/ERK pathway conveys growth factor and mitogen signalling 
to control the phosphorylation of a plethora of substrates regulating proliferation, 
survival, and migration. The Ras signalling pathway is frequently associated with poor 
prognosis and drug resistance in various cancers including those of the blood, breast 
and prostate. Activation of the downstream effector ERK does not always occur via a 
linear cascade of events; complicating the targeting of this pathway therapeutically. 
This work describes a novel positive feedback loop where the cell cycle regulatory 
factor Spy1 (RINGO; gene SPDYA) activates ERK1/2 in a MEK-independent fashion. 
Spy1 was originally isolated for the ability to stimulate Xenopus oocyte maturation via 
a MAPK-signalling pathway and is known to override apoptosis triggered by the DNA 
damage response. We demonstrate that mammalian Spy1-mediated ERK activation 
increases ligand-independent phosphorylation and activation of estrogen receptor 
α, correlating with a decrease in tamoxifen sensitivity. This could define a novel 
druggable mechanism driving proliferation and resistance in select cancers.
INTRODUCTION
Overall 5 year survival rates for breast cancer have 
increased by almost 20% since 1975, largely because of 
improved screening and drugs developed against estrogen 
signalling (ie. tamoxifen) and the Her2/Neu receptor 
(ie. trastuzumab) [1]. Despite these advances, a subset of 
patients either progress to, or initially present with, cancers 
that are unresponsive to current targeted therapies [2, 3]. 
As such, breast cancer remains the second leading cause 
of death from cancer among women [1]. Determining the 
mechanisms regulating the initiation and/or progression to 
a drug resistant status represents a current challenge in the 
breast cancer field.
This work focused on a cell cycle protein coined 
Spy1 (Speedy, RINGO) (gene SPDYA) that is elevated in 
a number of human cancers, including invasive carcinoma 
of the breast, as well as cancers of the liver, brain, and 
blood [4–12]. In the breast, Spy1 levels are elevated 
during proliferative stages of mammary development 
(puberty and pregnancy) and forced expression can drive 
mammary tumorigenesis [13]. Spy1 is one member of 
a family of ‘cyclin-like’ proteins that are expressed and 
degraded in a cyclic manner and are able to directly bind 
and activate the cyclin dependent kinases (CDK)s [14–16]. 
Spy1 functions in an atypical manner to classical cyclins 
in that it binds to both the G1/S and G2/M CDKs and 
directs phosphorylation of non-canonical CDK substrates 
[12, 17, 18]. Activation of the CDKs by Spy1 occurs 
independent of phosphorylation within the T-loop and 
dephosphorylation on defined inhibitory residues [17]. 
Further, Spy1 directly binds and promotes the degradation 
of the CDK inhibitor, p27Kip1 [8, 19]. Hence, Spy1 supports 
rapid progression through the cell cycle even in the face 
of senescence and apoptotic-inducing stimuli [4, 5]. This 
suggests a mechanism by which Spy1 overrides cell-cycle 
induced apoptosis caused by therapeutic agents, which 
could support drug resistance. 
Proliferative programs in the breast, both during 
normal development and breast cancer, are in part dictated 
by signalling through the steroidal estrogen receptor alpha 
(ERα). ERα changes into an active conformation upon 
binding to the ligand estradiol (E2) [20]. Classical ER 
activation promotes receptor homodimerization, nuclear 
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translocation and subsequent DNA binding to estrogen 
response elements (EREs) to regulate the expression of 
various genes [21]. ‘Non-classical’ genomic signalling 
also exists where the E2-ERα complex binds transcription 
factors to regulate genes lacking an ERE, like Cyclin 
D1 [22–25]. ER dimers, activated by E2 or other growth 
factors, can also interact and form complexes directly with 
G-proteins, receptor tyrosine kinases, and non-receptor 
tyrosine kinases [26]. Non-classical ER signalling can 
thereby trigger signal transduction pathways such as 
Ras/mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K/Akt) [27]. Collectively, 
ERα works via these diverse mechanisms to promote 
breast cell growth and survival [20, 28].
Tamoxifen functions by competitively binding 
to the ligand binding domain (LBD) of ERα, altering 
its conformation such that it can no longer bind to E2, 
hence, preventing E2 proliferative signalling [29]. The 
binding efficiency of tamoxifen can be altered by the 
phosphorylation status of residues within ERα capable 
of inducing ligand independent signalling [30, 31]. 
Phosphorylation on serine (S) 118 by extracellular signal-
regulated kinases (ERK)1/2 is one prominent example 
of such a modification. S118 phosphorylation promotes 
hypersensitivity to E2 and decreases ERα affinity for 
tamoxifen [30, 32–35]. ERK1/2 is the final kinase at the 
end of the Ras/MAPK signalling cascade, succeeding Ras, 
Raf and MEK activation. Given that non-classical ERα 
signalling can activate a MAPK cascade, this represents a 
feedback mechanism enforcing activity of the ER [23, 24, 
36–40]. 
The Ras-Raf-Mek-ERK cascade is hyperactivated 
in approximately 30% of human cancers; a large 
percentage characterised by a mutation in either the Ras 
or Raf genes [41, 42]. Constitutively activated MEK1/2 
is frequently seen in cancer cell lines, contributing to 
increased cell survival, migration and transformation 
[42]. Overexpression and hyperphosphorylation of 
ERK1/2 has been seen in various cancers, including 
hepatocellular carcinoma and breast cancer [41, 42]. 
Pharmacological intervention upstream of ERK1/2 has 
received considerable focus; however, to date clinical 
results are largely underwhelming, with preclinical 
and clinical documentation showing a development of 
acquired resistance shortly after receiving treatment 
[43, 44]. Resistance is largely associated with re-activation 
of ERK1/2 signalling [45]. As such, specific inhibitors of 
ERK1/2 have become a focus over the last 5 years. Use of 
an ERK1/2 inhibitor can overcome acquired resistance to 
both BRAF and MEK1/2 inhibitors in melanoma, breast 
and colon cancer cell lines [45, 46]. This exciting data has 
led to the introduction of the ERK1/2 inhibitor into phase I 
clinical trials for solid tumours [45, 47, 48]. Understanding 
the activation of all components of this pathway influences 
the successful intervention of a large number of cancers, 
including breast cancer. 
RESULTS 
Spy1 is upregulated downstream of the estrogen 
receptor
Spy1 is upregulated downstream of c-Myc and 
developmental expression patterns mimic that seen 
with c-Myc [13, 49]. Given that c-Myc is upregulated 
downstream of ERα [50]; we used ERα-positive MCF7 
breast cancer cells to determine whether Spy1 protein is also 
regulated downstream of ERα. Spy1 protein levels were 
elevated over a period of 1–6 hours following E2 treatment 
(Figure 1A). Protein levels were also elevated in response 
to E2 following reconstitution of ERα in ER negative 
HEK-293 cells (Figure 1B and 1C). These data indicate 
that upregulation of Spy1 protein levels occurs downstream 
of the estrogen signalling pathway. Overexpression of 
Spy1 in ER-positive MCF7 cells demonstrates a significant 
increase in the phosphorylation of the ER at S118 
(Figure 1D). To determine if this was due to enhanced 
proliferation through G1/S, the G1/S cyclin, Cyclin E1, 
was overexpressed and phosphorylation of ER-S118 
measured (Figure 1D). Elevated levels of Cyclin E1 had no 
significant change in ER-S118 phosphorylation. 
Spy1 is capable of promoting the activation of the 
MAPK pathway when injected into unfertilized Xenopus 
oocytes [16], and S118 is phosphorylated by several kinases 
including ERK1/2 of the MAPK pathway [30, 33, 51]. 
We measured the activity of ERK (phospho-T202/
Y204; pERK) in the presence of overexpressed Spy1 and 
found a significant increase in the level of phospho-ERK 
(Figure 1D), this was also seen in other cell systems 
(Supplementary Figure 1A–1B). While a slight increase 
in phosphorylation was also seen with Cyclin E1 
overexpression, this difference was not statistically 
significant. These data support that activation of ERK, 
seen downstream of Spy1 overexpression, is not a 
generalized effect due to cell proliferation. To determine if 
Spy1 is a necessary mediator of ERK activation, HEK-293 
cells were infected with shRNA lentivirus targeting two 
separate regions of the Spy1 mRNA (shSpy1.1, shSpy1.2). 
shRNA against Cyclin E1 was also used to address the 
essentiality of classical cyclin-CDK activation (shCyclinE) 
and a pLKO-shScrambled control (pLKO). Both of the 
shSpy1 constructs significantly decreased endogenous 
activated ERK levels (Figure 1E and Supplementary 
Figure 1C); this effect was not noted with shCyclinE 
treatment despite successful knockdown (Figure 1E and 
Supplementary Figure 1C; left panel representative blot). 
Spy1 effects were reversed by a rescue construct, showing 
specificity of the sh-targeting (resSpy1; Figure1E). These 
results support that Spy1 is a required component for 
activation of ERK1/2 in this cell culture system.
To determine whether one of ERK1 or ERK2 was 
preferentially affected by Spy1, bands were separated to 
easily differentiate the family members and blotted with 
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Figure 1: Spy1 is upregulated downstream of the estrogen receptor. (A) MCF7 cells were treated with 50 nM of estradiol (E2) 
or vehicle control (DMSO) over the indicated time course. Representative blot (left), densitometry averages Spy1 and S118 (right). (B–C) 
Hek-293 cells were transfected with pEGFP-C1-ERα. B-Representative blot confirming expression. C-Treatment with 50 nM of E2 over 
the indicated time course. Representative blot (left), densitometry averages for Spy1 (right). (D) MCF7 cells infected with control, Spy1, 
or Cyclin E1.(E) Cells were infected pLKO, 2 constructs of shSpy1.1, shSpy1.2, shCyclin E, or rescue vectors, followed by SDS-PAGE 
and IB. Representative blot (left), densitometry averages for relative ER-S118 (right). (F) Representative blot (upper panel) showing 
phosphorylation status of ERK1 and ERK2 using phosphor-specific antibodies for pERK threonine or tyrosine sites. Lower panel depicts 
quantification of both sites for either ERK1 (left) or ERK2 (right). Error bars reflect SE between at least 3 separate experiments. Student’s 
t-test was performed; *p < 0.05, **p < 0.01, ***p < 0.001.
Oncotarget23340www.impactjournals.com/oncotarget
phospho-threonine or phospho-tyrosine specific antibodies 
to recognize ERK1-T202/ERK2-T185 and ERK1-Y204/
ERK2-Y187 (Figure 1F). Our results show that Spy1 
significantly increases the level of phosphorylation on both 
ERK1 and ERK2 with statistically consistent results for 
the threonine site in each protein. For the remainder of the 
experiments we focused on the average phosphorylation 
status of these proteins using the general T/Y-ERK 
phospho-specific antibody. 
Spy1 activation of ERK1/2 is dependent on CDK 
activation
Using a previously characterized Spy1-CDK non-
binding mutant (Spy1-D90A) [17], we questioned whether 
the direct binding between Spy1 and the CDK is essential 
for activation of ERK1/2. Transient transfection with wild-
type Spy1 shows a significant increase in the activation 
of ERK1/2 (Figure 2A), and a significant increase in 
proliferation, as compared to control and D90 transfected 
cells (Figure 2B). These data support the hypothesis that 
the activation of ERK1/2 is dependent on Spy1-mediated 
CDK activity. It is notable that altered migration of the 
Spy1-D90A mutant on SDS page gel has been consistently 
reported in the literature [17]. Spy1 can bind to both 
CDK1 and CDK2 [6, 12, 17]. To determine which CDK 
is most influential on Spy1-activated ERK, cells were 
transfected with Myc-tagged Spy1 and low levels of either 
an HA-tagged CDK1or CDK2 dominant negative (DN) 
vector (CDK1 DN or CDK2 DN), or relevant controls. 
The concentration of DN vector transfected did not 
significantly impair growth alone; however, both CDK1 
and CDK2 DN vectors significantly impaired the ability 
of Spy1 to activate ERK1/2 (Figure 2C). Collectively, this 
data supports that Spy1-mediated phosphorylation of ERK 
requires at least one of the CDKs to be present and bound.
Spy1-mediated ERK1/2 activation is MEK-
independent
In the breast, Spy1 levels are elevated by MAPK/
ERK and c-Myc signalling to promote proliferation and 
override differentiation stimuli [13, 16]. In the presence 
of U0126, a MEK1/2 inhibitor, we see a decrease in 
endogenous pERK1/2, as well as a significant decrease 
in overall endogenous Spy1 protein levels, as seen 
previously [13]. In cells overexpressing Spy1, U0126 
does not significantly reduce the ability of Spy1 to 
activate ERK1/2 (Figure 3A), suggesting that Spy1 
activates ERK1/2 independent of MEK. Using a MEK1/2 
DN in combination with Spy1 overexpression, pERK 
continues to be significantly activated, further supporting 
a MEK-independent mode of activation (Figure 3B). 
Another level of regulation of ERK1/2 phosphorylation 
is through the steady state removal of phosphorylation 
by the relevant phosphatases. Four major phosphatases 
regulate ERK1/2; PP2A, MAPK Phosphatase (MKP)1, 
MKP2, and MKP3 [52]. We questioned whether Spy1 
expression could alter the expression level of any of 
these phosphatases. As seen in Figure 3C, neither Spy1 
or Cyclin E1 overexpression significantly decreased 
the protein levels of these phosphatases, Spy1 actually 
increased PP2A and MKP2 protein levels. It is intriguing 
to hypothesize that this is a cellular response to retain 
steady state due to enhanced activation of ERK1/2.
Spy1 activation of ERK is dependent on Ras and Raf
To determine whether alternate upstream activators 
of ERK1/2 are important in Spy1-mediated effects 
we tested the consequences of Spy1 overexpression 
in the presence of Ras and c-Raf inhibitors, Farnesyl 
Thiosalicyclic Acid and GW5074, respectively. When 
c-Raf or Ras are inhibited Spy1 is no longer able to 
activate ERK as compared to the control, indicating that 
the regulation of pERK by Spy1 requires both Raf and Ras 
activation (Figure 4A). Moeller et al. (2003) showed Ras 
activation requires the inhibition of p27. Binding of p27 
to Grb2 blocks the interaction of Grb2 with the guanine 
nucleotide exchange factor, SOS, thereby, inhibiting the 
formation of the Grb2/SOS complex, which is required 
to activate Ras [53]. Spy1-CDK2 can bind to and directly 
inhibit p27 [8, 19]. This work shows that Spy1 inhibits p27 
levels in the absence and presence of Raf/Ras inhibitors 
(Figure 4A, hollow bars), demonstrating that this aspect 
of Spy1 activity is intact and that ERK-mediated effects 
reside downstream of p27 degradation. To investigate the 
importance of the direct Spy1-p27 interaction, a Spy1-p27 
binding mutant (R170) was utilized [54]. Spy1-R170 
prevents the downregulation of endogenous p27 seen 
with Spy1-WT as previously published (Figure 4B) 
[54]. Interestingly, when cells were infected with R170 
lentivirus there was no statistical increase in ERK 
phosphorylation as seen with Spy1-WT (Figure 4C and 
Supplementary Figure 2). Collectively, these data show 
the Spy1-CDK complex requires the activation of Ras and 
depends on the direct interaction with p27 to significantly 
increase pERK protein levels. 
Spy1 overexpression may function through RIPK2
Receptor-interacting serine-threonine kinase 2 
(RIPK2) is phosphorylated and activated through Ras-
activated Raf kinase [55]. One established downstream 
substrate of RIPK2 is ERK1/2 in vitro and in vivo [55].
To determine whether the effects of Spy1 overexpression 
on ERK1/2 could be mediated through RIPK2, cells were 
transfected with Myc-tagged-Spy1 followed by infection 
with lentivirus packaging either scrambled control shRNA 
(pLKO) or shRNA targeting two different regions of the 
RIPK2 mRNA (shRIPK2.1, shRIPK2.2) (Figure 4D). In 
the presence of RIPK2 knockdown, a decrease in pERK1/2 
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levels was seen in comparison to Spy1 overexpression 
alone (Figure 4D). These results demonstrate that Spy1-
CDK1/2 can activate ERK1/2 indirectly through the Ras-
Raf-RIPK2 pathway. 
Increased levels of Spy1 reduce sensitivity to 
tamoxifen
Spy1 is found at elevated levels in aggressive 
forms of breast cancer [12]. Given the role of ERK 
signalling in driving tamoxifen resistance [33, 56], 
we tested the effect of Spy1 levels on the tamoxifen 
response. ER positive MCF7 cells were infected with 
pEIZ-Spy1 or empty vector control (pEIZ) (Figure 5A). 
Cells were treated with 100 nM tamoxifen for 24 hours 
and subjected to the trypan blue exclusion assay. Spy1 
overexpression significantly increased cell number as 
compared to pEIZ control in untreated cells, as has 
been previously published [57]. Interestingly, when 
tamoxifen was added, Spy1 continued to drive cell 
proliferation, but pEIZ control populations failed to 
proliferate (Figure 5A), supporting that elevated levels of 
Spy1 reduced sensitivity to tamoxifen. We implemented 
a zebrafish xenograft model to elucidate whether Spy1 
Figure 2: Spy1-mediated ERK phosphorylation is CDK dependent. (A–C) Hek-293 cells were transfected with the indicated 
constructs (along top of each representative blot and X-axis of each graph, including the empty vector control (pCS3). (A) Representative 
blot (left). Densitometry for Spy1 or pERK over multiple experiments (right). (B) Trypan blue exclusion assay was performed after 
24 hours of incubation, total cell numbers presented. (C) Representative blot (left). Densitometry (right) as represented on Y-axis. Error bars 
reflect SE between at least 3 experiments. Student’s t-test was performed; *p < 0.05, **p < 0.002, ***p < 0.001.
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levels can increase or decrease sensitivity to tamoxifen 
in vivo. The use of zebrafish xenograft models in cancer 
and drug therapeutics discovery has been recognized 
and validated as a suitable alternative to mammalian 
models, with several important advantages [58]. Drug 
toxicity studies show reliable screening in the zebrafish 
and that this model is a suitable predictive alternative to 
mammalian systems [59, 60]. Furthermore, key cell cycle 
mediators, tumour suppressors, oncogenes, and estrogen-
responsive genes and activation of downstream pathways 
of estrogen signalling are all highly conserved in the 
zebrafish [61]. Additionally, injection of human breast 
Figure 3: Spy1-mediated ERK phosphorylation is MEK-independent. (A–C) Hek-293 cells were infected (A) or transfected 
(B and C) with the indicated constructs (along top of each representative blot and X-axis of each graph. (A) Cells were treated with 10 µM 
U0126 or vehicle control (DMSO). (A–C) Representative blot (left). Densitometry (right) as represented on Y-axis or text box. Error bars 
reflect SE between at least 3 experiments. Student’s t-test was performed; *p < 0.05, **p < 0.002, ***p < 0.001.
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Figure 4: Spy1 activation of ERK1/2 is dependent on Ras and Raf. Hek-293 cells were transfected (A) or infected (B–D) with 
constructs indicated at the top of each blot (left). (A and C) were treated with inhibitors as indicated on the panels. (A, C–D) Densitometry 
of relative protein levels conducted over all experiments (right). Lower right panel (C) fold change ratio of pERK:Spy1 protein levels. Error 
bars reflect SE between at least 3 experiments. Student’s t-test was performed;*p < 0.05,**p < 0.01, ***p < 0.001.
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cells followed by therapeutic drug testing in zebrafish is 
more efficient than using immunocompromised mice since 
the adaptive immune system does not develop until 14 
days post fertilization (dpf) and, hence, tumour responses 
can be studied in the presence of residual immune 
competence [62]. The zebrafish model also allows for 
high throughput testing of drug combinations in a short 
time frame, being both cost and time efficient. To validate 
the model, fluorescently labelled MCF7 or tamoxifen 
resistant LCC9 cells [63] were injected into embryos at 48 
hours post-fertilization (hpf) and treated with tamoxifen 
for 24 hours (Supplementary Figure 3). Fish were imaged 
and quantified before and after treatment to determine the 
changes in number of tumour foci per fish, as quantified by 
total fluorescence. Tumour foci at 24 hours post-treatment 
(hpt) demonstrate that while the MCF7 cells respond 
to treatment, the LCC9 cells are resistant to tamoxifen 
treatment (Supplementary Figure 3). Sensitive MCF7 
cells were then infected with pEIZ control or pEIZ-Spy1 
vectors and injected into zebrafish embryos (Figure 5B). 
Vehicle control (DMSO) or tamoxifen was administered 
48 hours post-implantation (hpi) and tumour foci were 
imaged for each fish at 0 hpt and 24 hpt. The fold change 
in tumour foci was recorded for each individual embryo to 
control for variation in injected cell number (quantification 
lower graph). Tamoxifen had a significant effect on overall 
cell numbers in control infected cells, which may be a 
combination of cytostatic and cell death effects. However, 
when Spy1 was overexpressed there was a significant 
decrease in sensitivity to tamoxifen treatment in vivo 
(Figure 5B; lower panel). 
Targeting Spy1-directed ERK activation 
sensitizes cells to tamoxifen
We have demonstrated that Spy1 activates ERK, 
and subsequent phosphorylation of ERα-S118 in a MEK-
independent, but Ras-dependent, fashion (Figures 3–4). To 
test whether Spy1 effects on tamoxifen sensitivity were 
mediated through this pathway, MCF7 cells were treated 
with tamoxifen in the presence or absence of the MEK 
inhibitor U0126. When Spy1 levels were elevated, even 
in the presence of tamoxifen, the levels of pERα-S118 
were significantly increased as compared to control and 
Cyclin E1overexpression and this occurred in a MEK-
independent fashion (Figure 6A–6B). We then measured 
the effect of direct inhibition of ERK1/2 on Spy1-mediated 
effects on pERα-S118. MCF7 cells overexpressing Spy1 
or control were treated with 10 µM ERK1/2 inhibitor 
(SCH772984), either alone or in combination with 100 nM 
tamoxifen (Figure 6C). Spy1 significantly increases 
pERα-S118 in control situations but not in the presence of 
the ERK inhibitor (with or without Tamoxifen). Cells were 
then counted for viability after treatment using the trypan 
blue exclusion assay. We show that the use of the ERK1/2 
inhibitor alone significantly reduces the number of viable 
cells in both control and Spy1 overexpressing cells 
(Figure 6D). Importantly, Spy1-mediated proliferation 
was not abrogated by tamoxifen alone but ERK inhibition 
prevented Spy1-mediated effects on growth (Figure 6D; 
tamoxifen lanes).
Collectively, these data show that Spy1, an atypical 
cell cycle protein expressed at elevated levels in many 
human cancers, alters the post-translational status of the ER 
and abrogates response to hormone therapy through ERK1/2 
activation. Novel therapies focusing on the direct inhibition 
of ERK1/2 in patient populations harbouring elevated levels 
of Spy1 may represent a novel therapeutic direction for both 
treating drug resistant patients and preventing/decreasing the 
incidence of resistance in ER-positive patients. 
DISCUSSION
In breast cancer estrogen can independently regulate 
the expression and function of the proto-oncogene c-Myc 
followed by a rapid activation of the G1 CDK, CDK2, 
to induce cell cycle progression [25, 64, 65]. Previous 
reports have perplexed that following estrogen treatment 
there is little or no change in the levels of Cyclin E, CDK2 
or in the formation of cyclin E–CDK2 complexes prior 
to entry into S phase [66]. This work demonstrates that 
the atypical cyclin partner for CDK2, Spy1, is transiently 
upregulated downstream of activated ERα. This reveals a 
novel pathway for exploration important both to normal 
development and a host of pathologies. It is interesting to 
note that a shift in the mobility of Spy1 was seen upon the 
addition of E2. Whether this is due to a post-translational 
modification on Spy1 will require further examination. 
Additionally, we have shown that Spy1 can induce a 
unique activation of ERK1/2 that may in part dictate ER-
mediated proliferation in some ER+ breast cancer cells.
It is important to note that post-translational 
modification of the ERK1/2 complex is a transient and 
highly dynamic process [67]. Our data demonstrates that 
at any specific time breast cancer cells with elevated levels 
of Spy1 have higher activated ERK1/2 as measured by 
a general phospho-antibody. Our data further suggests 
that this is indirect, introducing even more variability 
in the dynamics of the event. Further investigation 
into the specific phosphorylation sites on each ERK 
isoform showed a significant increase in the level of 
phosphorylation on both sites of ERK2 (T185 and Y187), 
but only one site of ERK1 (T202). More work would be 
required to determine if there is any site specificity. It is 
enticing to consider that perhaps Spy1-CDK mediated 
signalling could have some direct effects on the post-
translational status of the MAPK pathway or direct 
effectors. Interestingly, Spy1-CDK activation of ERK is 
unique to Spy1 in that Cyclin E overexpression did not 
demonstrate a statistically significant change in ERK 
activation over multiple repetitions. It is notable that we 
have seen variability in the effects of Cyclin E on ERK 
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Figure 5: Spy1 levels affect tamoxifen response in vivo. (A) MCF7 cells were infected with indicated constructs (along top of 
representative blot and X-axis of graph). Trypan blue exclusion assay was performed over indicated time course in the presence or absence 
of tamoxifen. Error bars reflect SE between triplicate experiments. (B) Representative images of injected zebrafish larvae expressing either 
empty control vector (top panel) or Spy1 overexpression vector (bottom panel) before (0 hpt) and after (24 hpt) treatment with either DMSO 
or 10 µM tamoxifen. *The same fish is depicted at 0 and 24 hpt for each condition. Scale bar = 200 µm. Graph representing the mean fold 
change in foci, as quantified by fluorescence as compared to 0 hpt. n = 28–46 fish/treatment (excluding mortalities). Student′s t-test was 
performed; ns = not significant, **p < 0.01, ***p < 0.001. Scale bar = 200 µm.
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Figure 6: Spy1 levels regulate the response to tamoxifen. MCF7 cells were infected with constructs indicated at the top of each 
representative blot and X-axis of each densitometry graph. Drug treatments are indicated in each panel. Tamoxifen (100 nM), MEK1/2 
inhibitor (10 µM), ERK inhibitor (10 µM) and control MEK/ERK inhibitors (10 µM). (A) Representative blot (left) of pS118 without 
tamoxifen treatment. (B) Representative blot (left) and quantification of pS118 (right). (C) Representative blot (left) and quantification 
of pS118 (right). (D) Viable cell numbers after treatment assayed using trypan blue exclusion. Error bars reflect SE between at least 3 
individual experiments. Student’s t-test was performed; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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activation that do not preclude that Cyclin E may activate 
ERK under specific experimental conditions. 
ERα proliferative signalling in breast cancer cells is 
dependent upon ligand binding and/or post-translational 
modification to enable signalling in the absence of ligand. 
Post-translational modifications to ERα can render the 
receptor ligand-independent and resistant to anti-estrogen 
therapies. Phosphorylation on S118 of ERα is one such 
modification that can lead to tamoxifen resistance [51]. 
Cellular cycling influences the phosphorylation status 
of ERα in a manner that is dependent upon mitogen 
stimulation [25, 68]. In particular, phosphorylation on 
S118 is regulated by activated ERK1/2 [33, 34, 51]. 
This work demonstrates that Spy1 levels correlate with 
an increase in phosphorylation of S118 on ERα in a 
manner dependent on ERK1/2 activity, thereby providing 
a direct link between ER modification and the cell cycle 
machinery. 
Lenormand et al. (1999) showed that Spy1 could 
activate MAPK in Xenopus oocytes [16]. Unlike the 
Lenormand data, however, Spy1 activation of ERK1/2 
in the human breast cell line, MCF7, appears to be 
independent of MEK, and at least in part dependent on 
the direct interaction between Spy1 and the cell cycle 
inhibitor p27. Our work is not the first to show a MEK-
independent activation of ERK1/2, Aksamitiene et al. 
(2010), have demonstrated that ERK1/2 can be activated 
in a MEK-independent, but PI3K/Akt-sensitive fashion, 
in the ER-positive breast cancer cell line T47D [69]. Our 
data supports that upstream pathways driven by Spy1 may 
converge on an activation of the novel ERK activator 
RIPK2 (See Figure 7).
Mutations within Ras and Raf, or hyperactivation of 
MEK1/2 has spurred the production of pharmacological 
inhibitors targeting mediators upstream of ERK1/2; 
however, resistance and relapse occurs within 6 to 7 
months of treatment [45]. Our findings may suggest that in 
some cancers with an elevated Spy1 overexpression small 
molecule inhibitors for MEK1/2 may be ineffective. Indeed, 
we have shown elevated levels of Spy1 alone can override 
MEK1/2 inhibitors and increase the phosphorylation status 
of ER on S118. Since ERK1/2 activation significantly 
promotes uncontrolled cell growth, survival, and invasion, 
determining a way to suspend ERK1/2 activation by Spy1 
could have clinical implications for tamoxifen resistance 
and breast cancer therapies in at least subsets of patients. 
A significant decrease in cell viability and a concomitant 
decrease in phosphorylation of ERα-S118 in the presence 
of elevated Spy1 was seen only when ERK1/2 was directly 
inhibited. The discovery of a new inhibitor specifically 
targeting the ATP-binding site of ERK1/2 has shown 
promising results with respect to solid tumours [45, 46]. 
Indeed, our data herein shows that inhibition of ERK1/2 
results in an abrogation of S118-ERα phosphorylation and 
a significant restoration of response to tamoxifen treatment 
in ER+ cells with elevated Spy1 levels. Hence, therapies 
focusing on the direct inhibition of ERK1/2 in ER+ patient 
populations harbouring elevated levels of Spy1 may 
represent an effective therapeutic direction for preventing/
decreasing resistance to hormone therapy. 
Figure 7: Schematic diagram of proposed pathway. Our data supports that elevated levels of Spy1 can act upstream to activate 
ERK1/2 through a MEK-independent pathway. Our data supports that this depends on a direct interaction with p27, as well as Ras and 
Raf activation. A novel pathway has been described demonstrating a Raf downstream kinase, RIPK2 [55] capable of activating ERK1/2 
in a MEK-independent fashion. Our data shows a dependence of Spy1-mediated effects on RIPK2. Spy1-mediated ERK1/2 activation can 
phosphorylate the ER on S118 and alter sensitivity to tamoxifen.
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MATERIALS AND METHODS
Cell culture
Human embryonic kidney (HEK)-293 and MCF7 
cells were purchased from ATCC and were subcultured 
in DMEM media supplemented with 10% FBS and 
30,000 units penicillin/30,000 µg streptomycin solution. 
Cells were maintained under normoxic conditions 
(5% CO2) at 37°C. LCC9 cells (Lombardi Comprehensive 
Cancer Center, Georgetown University) were routinely 
subcultured in DMEM phenol red free media supplemented 
with 1 mM L-glutamine, 30,000 units penicillin/30,000 
µgstreptomycin,and 10% charcoal treated FBS. Cells were 
maintained under normoxic conditions (5% CO2) at 37°C.
Plasmids
Creation of the Myc-Spy1-pCS3 was described 
previously [57].Plasmids for Rc-CMV-Cyclin E (#8963), 
pEGFP-C1-ERα (#28230), HA-CDK1-DN (#1889), DN9 
(Mek1 dominant negative; #21209), and pLKO-scrambled 
control (#8453) were purchased from Addgene. pLKO-
shSpy1 and pLKO-shCyclin E were cloned to express a 
short hairpin previously described to knockdown Spy1 and 
Cyclin E respectively and are previously described [7]. 
Control pLKOcontains a scrambled sequence previously 
described [7]. The CDK mutants D90 [17] and R170 
vectors [54] have been previously described. pEIZ vector 
was generously donated from Dr. B. Welm (Univ. of Utah). 
The creation of pEIZ-Spy1 was completed by inserting 
Spy1 oligo into the EcoRI and XbaI sites of pEIZ.
Immunoblotting (IB)
Whole cell lysates were prepared as described 
previously [12] and aliquots of lysates containing 100 µg 
protein were subjected to electrophoresis on denaturing 10% 
SDS polyacrylamide gels and transferred to PVDF-Plus 
0.45 micron transfer membrane (Osmonics Inc.) for 2 hours 
at 30 volts using a wet transfer method. Chemiluminescent 
Peroxidase Substrate was used for visualization following 
manufacturer’s instruction (Pierce). Chemiluminescence 
was quantified on an AlphaInnotech HD2 (Fisher) using 
AlphaEase FC software.
Antibodies
Actin was purchased from Chemicon-Millipore 
(MAB150 1R). Spy1 was purchased from ThermoScientific 
(PA5-29417). c-Myc (9E10, C3956)and secondary rabbit 
and mouse antibodies were purchased from Sigma. 
Phospho-ERα-S118 (ab32396), Cyclin E1 (ab33911), 
phospho-Raf1 (ab135559), p27 (ab7961), anti-ERK1 
(phospho T202) + ERK2 (phospho T185) (ab201015), 
and anti-ERK1 (phospho Y204) + ERK2 (phospho Y187) 
(ab47339) were purchased from Abcam. ERα (sc-543), 
RIPK2 (sc-8610), ERK1/2 (sc-154), MKP1 (sc-271684), 
MKP2 (sc-1200), MKP3 (sc-8598), PP2A (sc-6110), 
and Raf1 (sc-7267) were purchased from Santa Cruz 
Biotechnology. Phospho-ERK 1/2 (Thr 202/Tyr 204)was 
purchased from Cell Signaling (4370). 
Transfection/infection
Transfection
Cells were transfected using polyethylenimine (PEI) 
branched reagent (Sigma, 408727). In brief, 10 µg of DNA 
was mixed with 3 µl of 10 mg/ml PEI for 10 minutes then 
added to a 10 cm tissue culture plate. Transfection media 
was changed after 24 hours.
Infection
8000 cells were seeded in fully supplemented growth 
media in 96-well plates for 2 hours. Cells were starved by 
removing serum and penicillin/streptomycin from the media, 
followed by the use of 1 mg/ml polybrene (Santa Cruz, sc-
134220) and MOI 3 of the specific vector used. Infected 
media was changed to fully supplemented media 24 hours 
after infection. For knockdown, cells were incubated with 
1mg/ml puromycin (Sigma, P8833) 48 hours after infection 
for 72 hours to allow for puromycin selection. Media is 
thereafter changed every 48hours with puromycin included.
Inhibition treatments
HEK-293 cells were seeded equally in 10 cm dishes 
at a density of 5 × 105 cells. Upon 80% confluency, HEK-
293 cells were incubated with either 10 µM SB202474 
(control; EMD Millipore, 559387) or 10 µM U0126 
(MEK 1/2; EMD Millipore, 662005) inhibitors for 1 hour. 
For Raf inhibition, 5 µM GW5074 (Sigma, G6416) was 
added to the cells for 24 hours. For Ras inhibition, 20 µM 
Farnesyl Thiosalicyclic Acid (Santa Cruz, sc-205322) was 
added to the cells for 24 hours. For ERK1/2 inhibition, 
10 µM SCH772984 (ApexBio, A3805) was added to the 
cells for 1 hour prior to treatment with tamoxifen (Sigma, 
H7904) for 24 hours. Following drug treatment, cells were 
either analyzed using trypan blue analysis or pelleted, 
lysed and analyzed using 10% SDS-PAGE. 
Estradiol treatments
MCF7 were seeded equally in 10 cm dishes at 
a density of 5 × 105 cells. Upon 70% confluency, the 
cells were treated with phenol red-free RPMI media, 
supplemented with 10% charcoal treated FBS and 30,000 
units penicillin/streptomycin. After 48 hours, cells were 
incubated with either dimethyl sulfoxide (DMSO) or 
50 ng/ml E2 (Sigma, E8875) for specified time points, 
followed by cell harvesting for protein extraction and IB.
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Animal care and handling
Wildtype Zebrafish (Daniorerio) were handled in 
compliance with local animal care regulations and standard 
protocols of Canada and following the University of 
Windsor animal care protocol #12–14. Adult fish were kept 
at 28.5°C and bred according to available protocols [56].
Implantation and treatment
Eggs were collected after fertilization and kept in 
E3 embryo media (5 mM NaCl, 0.17 mMKCl, 0.33 mM 
CaCl2, 0.33mM MgSO4, 10
–5% Methylene Blue) at 32°C in 
an incubator until ready to inject. Before injection 200,000 
cells were reconstituted in 200 µL of serum-free media and 
labelled with 1 µL of DiO (green) (Vybrant, Invitrogen) 
at 37°C for 20 minutes. Cells were washed with 200 µL 
of serum free media twice and resuspended in 20 µL of 
serum free media, kept at 37°C for 20 minutes, and placed 
on ice until injection. 48 hours post-fertilization (hpf) 
the embryos were dechorionated with fine tip forceps 
and anesthetised with 0.168 mg/ml of Tricaine (Sigma, 
MS222). 50–100 labelled cells/ 9 nL were loaded into 
glass capillary needles and injected into the yolk sac of 
each embryo using a Nanoject II (Fisher Scientific). After 
injection, embryos were placed in E3 embryo media and 2 
hours post-implantation (hpi) were examined using a Leica 
fluorescence stereoscope to exclude any embryo with cells 
outside of the implantation area. Mortalities due to injection 
will also be evident at this time point for exclusion (~5–
15%). 24 hpi (0 hours post-treatment (hpt)) the embryos 
were anesthetized, imaged and placed in a 96-well plate; 
one embryo per well. At 48 hpi the embryos were treated 
with either DMSO or 10 µM tamoxifen. The embryos were 
imaged at 0 hpt and 24 hpt and the fold change in tumour 
foci were quantified by total fluorescence.
Image analysis
The fish were imaged before and after treatment with 
Tamoxifen and DMSO. The image for each embryo was 
imported into ImageJ, the image was converted to a 32-bit 
greyscale, and the threshold was adjusted to eliminate 
background pixels. Total area of fluorescence was measured 
as the tumour area and the ‘particle analysis’ function was 
used to calculate number of tumour foci. Using automated 
software we aligned the site of injection over multiple fish 
to determine overall changes in the distance that tumour 
foci are detected from injection site. All measured results 
were copied into Excel files and fold change in tumour area 
and tumour foci calculated from 24 to 72 hpi.
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